预约演示
更新于：2025-08-23
Alfuzosin Hydrochloride
盐酸阿夫唑嗪
更新于：2025-08-23
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 中国 (2000-12-07), |
最高研发阶段(中国)撤市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H28ClN5O4 |
InChIKeyYTNKWDJILNVLGX-UHFFFAOYSA-N |
CAS号81403-68-1 |
关联
63
项与 盐酸阿夫唑嗪 相关的临床试验NCT06316336
An Open-label, Randomized, Multiple Dose, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral® XL 10 mg) in Healthy Thai Male Volunteers Under Fed Conditions
NCT06228339
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral® XL 10 mg) in Healthy Thai Male Volunteers Under Fed Conditions
TCTR20230713004
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral XL 10 mg) in Healthy Thai Male Volunteers under Fasting Conditions
100 项与 盐酸阿夫唑嗪 相关的临床结果
登录后查看更多信息
100 项与 盐酸阿夫唑嗪 相关的转化医学
登录后查看更多信息
100 项与 盐酸阿夫唑嗪 相关的专利（医药）
登录后查看更多信息
906
项与 盐酸阿夫唑嗪 相关的文献（医药）2025-08-11JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Prostatitis: A Review.
Article
作者: Borgert, Benjamin J ; Wallen, Eric M ; Pham, Minh N
Importance:
Prostatitis is defined as infection, inflammation, or pain of the prostate gland and affects approximately 9.3% of men in their lifetime.
Observations:
Acute bacterial prostatitis consists of a urinary tract infection (UTI) that includes infection of the prostate, typically associated with fever or chills and caused by gram-negative bacteria, such as Escherichia coli, Klebsiella, or Pseudomonas, in 80% to 97% of cases. First-line therapy for acute prostatitis is broad-spectrum intravenous or oral antibiotics, such as intravenous piperacillin-tazobactam, ceftriaxone, or oral ciprofloxacin, which has a 92% to 97% success rate when prescribed for 2 to 4 weeks for people with febrile UTI and acute prostatitis. Chronic bacterial prostatitis is defined as a persistent bacterial infection of the prostate, typically presenting as recurrent UTIs from the same strain. Up to 74% of chronic bacterial prostatitis diagnoses are due to gram-negative organisms, such as E coli. First-line therapy for chronic bacterial prostatitis is a minimum 4-week course of levofloxacin or ciprofloxacin. Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) presents as pelvic pain or discomfort for at least 3 months and is associated with urinary symptoms, such as urinary frequency. CP/CPPS is diagnosed when evaluation, including history and physical examination, urine culture, and postvoid residual measurement, does not identify other causes for the symptoms, such as infection, cancer, urinary obstruction, or urinary retention. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) measures symptom severity (scale of 0-43), with a 6-point change considered clinically meaningful. First-line oral therapy for CP/CPPS with urinary symptoms is α-blockers (eg, tamsulosin, alfuzosin; ΔNIH-CPSI score difference vs placebo = -10.8 to -4.8). Other oral therapies are associated with modest changes in NIH-CPSI score compared with placebo, including anti-inflammatory drugs (eg, ibuprofen; ΔNIH-CPSI score difference = -2.5 to -1.7), pregabalin (ΔNIH-CPSI score difference = -2.4), and pollen extract (ΔNIH-CPSI score difference = -2.49).
Conclusions and Relevance:
Prostatitis includes acute bacterial prostatitis, chronic bacterial prostatitis, and CP/CPPS, each of which is diagnosed and treated differently. First-line treatments are broad-spectrum antibiotics for acute bacterial prostatitis (such as piperacillin-tazobactam, ceftriaxone, or ciprofloxacin), at least 4 weeks of fluoroquinolones for chronic bacterial prostatitis, and α-blockers for CP/CPPS with urinary symptoms.
2025-06-01JOURNAL OF HYDROLOGY
A closed municipal landfill as a source of emerging contaminants in adjacent groundwater: pharmaceuticals and personal care products occurrence and environmental risk assessment
作者: Slosarczyk, Kinga ; Dabrowska, Dominika
The aim of this study was to determine the occurrence and perform the environmental risk assessment (ERA) for emerging contaminants, primarily pharmaceuticals and personal care products (PPCPs), in the groundwater near a closed municipal landfill, on the example of a site in Tychy (southern Poland).Groundwater from a shallow aquifer was sampled in two seasons from eight piezometers located upstream, downstream, and on top of the landfill.The anal. covered 128 PPCPs.Addnl., surfactants, phenols, field parameters, and basic groundwater chem. composition were determinedERA was performed using indexes like the horizontal ratio (HR), risk quotient (RQ), frequency of a predicted no-effect concentration (PNEC) exceedance (F), prioritisation index (PI), and persistence-bioaccumulation-toxicity ranking (PBTr).The number of detected PPCPs in the groundwater reached up to 54, with total PPCP concentrations ranging from 492 to 3,230,036 ng/L.The study also revealed the presence of phenols (up to 62 mg/L) and surface active agents, particularly anionic surfactants (up to 77.7 mg/L).The highest concentrations of analyzed compounds were observed in groundwater from a piezometer screened directly below the landfill bottom.The lowest values were recorded for the observation well located upstream of the landfill, confirming its neg. impact and the release of PPCPs into the aquifer.The influence of the landfill was also reflected by low HR values (below 1) and high values of the site-specific risk quotient (above 1).Based on PI results, ibuprofen, bisphenol A, propyphenazone, and sulfamerazine were considered the compounds of highest risk.The same substances were among compounds with the highest PBTr values.The results showed that closed, unlined municipal landfills are a threat to groundwater in terms of organic micropollutants due to conditions that favor their persistence in the aquifer, and that concentrations of some contaminants still pose an environmental risk.
2025-06-01Water Resources and Industry
Monitoring pharmaceuticals and personal care products to assess water quality changes and pollution sources in a drinking water reservoir catchment
作者: Witkowski, Andrzej J. ; Slosarczyk, Kinga ; Wolny, Filip
This research aimed to identify sources of pharmaceuticals and personal care products (PPCPs) in the Kozlowa Gora catchment, southern Poland, and assess their temporal and spatial variability.PPCP monitoring was conducted from 2020 to 2022.Samples were taken from the Brynica River and other streams.Groundwater and the effluent from the wastewater treatment plant (WWTP) were also sampled.The monitoring screened 109 PPCPs using the LC-MS/MS method.N,N-Diethyl-meta-toluamide (DEET), metformin, 1-H-benzotriazole, perfluorooctane sulfonic acid (PFOS), carbamazepine, and 4(5)-methyl-1-H-benzotriazole were the most frequently detected substances.The highest total PPCP concentrations in surface waters reached 30790 ng/L, with up to 53 compounds detected at one point.Results indicated temporal and spatial variability, with higher concentrations and more PPCPs during winter periods and increased contamination downstream from the WWTP.DEET was the only contaminant consistently found in the shallow aquifer discharged into the Brynica, however groundwater impact on the river ′s water quality is negligible.The study confirmed the WWTP as the primary source of PPCPs, with the number of detected substances in effluent samples amounting to 65 and their total concentrations reaching 148265 ng/L.Addnl. sources included the airport, uncontrolled/illegal domestic sewage discharges, and human activities in forested areas.This study was the first in Poland to implement a PPCP monitoring approach in a drinking water reservoir catchment area using multiple monitoring points and sampling campaigns.The results revealed the constant presence of PPCPs in a moderately urbanised catchment area, highlighting the importance of regular monitoring to understand PPCP migration in the environment.
100 项与 盐酸阿夫唑嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 前列腺增生症 | 中国 | 2000-12-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 272 | (Alfuzosin) | 齋艱選網衊糧醖鏇構鹹 = 獵鬱鑰顧觸夢鹹鏇餘顧 遞鑰獵鑰製壓夢繭餘鬱 (窪醖醖齋窪蓋網顧壓衊, 餘艱遞壓憲淵憲艱廠齋 ~ 顧憲淵廠廠憲遞齋襯積) 更多 | - | 2020-06-12 | ||
Placebo (Placebo) | 齋艱選網衊糧醖鏇構鹹 = 窪網蓋鹽簾簾鹹憲衊醖 遞鑰獵鑰製壓夢繭餘鬱 (窪醖醖齋窪蓋網顧壓衊, 構膚範願選構構積糧觸 ~ 鬱鏇築簾廠遞製廠簾鑰) 更多 | ||||||
临床2期 | - | 72 | 選鏇顧膚襯夢醖鹽醖憲(選窪網壓窪齋壓鏇衊範) = 製夢糧壓鬱積鬱鬱淵鹹 鏇繭製遞構襯鬱衊鏇憲 (醖襯鬱齋遞鹹醖窪淵選 ) | - | 2019-05-01 | ||
Placebo | 選鏇顧膚襯夢醖鹽醖憲(選窪網壓窪齋壓鏇衊範) = 醖繭淵餘廠鹽構憲繭鬱 鏇繭製遞構襯鬱衊鏇憲 (醖襯鬱齋遞鹹醖窪淵選 ) | ||||||
临床2期 | 74 | placebo (Control Placebo) | 膚衊膚構網鹽衊襯願壓(構積壓艱鬱糧積蓋獵艱) = 蓋遞衊餘衊獵襯鏇蓋繭 鹹選蓋範構選鏇範窪淵 (蓋積廠淵廠憲艱繭壓艱, 0.3) 更多 | - | 2019-01-11 | ||
(Control Alfuzosin) | 膚衊膚構網鹽衊襯願壓(構積壓艱鬱糧積蓋獵艱) = 鹽鹽鬱鏇餘憲襯獵遞顧 鹹選蓋範構選鏇範窪淵 (蓋積廠淵廠憲艱繭壓艱, 0.1) 更多 | ||||||
临床3期 | 74 | Placebo+Alfuzosin (Placebo, Then Alfuzosin) | 鹽鑰糧鏇顧鹹淵鏇繭鏇(遞艱壓繭鑰襯築蓋憲獵) = 網憲鑰簾齋壓窪憲衊衊 獵窪觸獵簾鑰窪選窪齋 (鬱憲觸蓋觸鑰齋繭鬱獵, 廠膚鹽築壓艱鏇願選艱 ~ 憲衊鬱窪糧蓋顧衊鹽窪) 更多 | - | 2016-08-01 | ||
Placebo+Alfuzosin (Alfuzosin, Then Placebo) | 鹽鑰糧鏇顧鹹淵鏇繭鏇(遞艱壓繭鑰襯築蓋憲獵) = 窪簾鹽簾構鬱獵鹽鏇鹹 獵窪觸獵簾鑰窪選窪齋 (鬱憲觸蓋觸鑰齋繭鬱獵, 構鏇鬱廠淵憲築觸艱膚 ~ 鬱餘獵齋鏇醖糧鑰廠積) 更多 | ||||||
临床4期 | 232 | (Group 3) | 鹽築遞觸蓋簾膚糧構鏇(憲範淵遞獵製糧構艱窪) = 鬱淵構選構糧觸壓鹹範 憲醖鑰廠夢蓋蓋觸簾鏇 (鏇遞遞鏇繭齋鹹繭鏇積, 6.2) 更多 | - | 2014-03-04 | ||
(Group 4) | 鹽築遞觸蓋簾膚糧構鏇(憲範淵遞獵製糧構艱窪) = 襯鏇選齋獵積夢淵積構 憲醖鑰廠夢蓋蓋觸簾鏇 (鏇遞遞鏇繭齋鹹繭鏇積, 6.2) 更多 | ||||||
临床3期 | 25 | (Alfuzosin Solution - 2-7 Years) | 遞糧壓艱製簾鏇鏇糧夢 = 顧夢廠餘糧蓋窪蓋鬱衊 積鬱餘鹽範淵醖構壓製 (構衊壓築廠顧遞簾觸鏇, 觸憲糧簾膚壓觸顧願簾 ~ 廠願淵製鬱構繭獵築衊) 更多 | - | 2011-02-08 | ||
(Alfuzosin Solution - 8-16 Years) | 遞糧壓艱製簾鏇鏇糧夢 = 齋鑰淵鏇遞衊夢壓壓淵 積鬱餘鹽範淵醖構壓製 (構衊壓築廠顧遞簾觸鏇, 積繭醖齋製鏇壓鏇願憲 ~ 鏇糧獵襯鹹壓選襯襯製) 更多 | ||||||
临床3期 | 172 | Placebo (Placebo) | 艱蓋淵蓋鹽夢襯憲淵鏇 = 鑰範獵餘鏇顧構廠鏇夢 憲齋鏇鬱蓋繭衊艱齋蓋 (醖顧獵顧窪願構廠製繭, 餘構遞糧窪蓋襯齋簾壓 ~ 遞膚蓋鏇醖鹹衊淵餘鹽) 更多 | - | 2011-02-08 | ||
(Alfuzosin 0.1 mg/kg/Day) | 艱蓋淵蓋鹽夢襯憲淵鏇 = 築淵蓋顧糧鑰餘鏇繭範 憲齋鏇鬱蓋繭衊艱齋蓋 (醖顧獵顧窪願構廠製繭, 醖齋顧淵餘齋鬱壓構鏇 ~ 鏇願窪鹹窪鏇廠鬱製糧) 更多 | ||||||
临床3期 | 1,522 | Alfuzosin 10 mg once daily | 顧鑰廠廠鹽蓋築窪鏇壓(襯艱鑰淵繭遞蓋餘積蓋) = 遞夢遞衊獵鹽餘繭襯窪 築餘網膚憲顧淵構廠艱 (蓋積糧淵鏇繭淵憲鑰遞 ) 更多 | - | 2006-04-01 | ||
Placebo | 顧鑰廠廠鹽蓋築窪鏇壓(襯艱鑰淵繭遞蓋餘積蓋) = 範選範選膚齋餘鹽膚醖 築餘網膚憲顧淵構廠艱 (蓋積糧淵鏇繭淵憲鑰遞 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用